Arresto Biosciences

Arresto Biosciences, Inc. was a privately-held, development-stage biotechnology company headquartered in Palo Alto, California, focused on medicines to treat fibrotic diseases and cancer by targeting enzymes involved in the synthesis of the extracellular matrix. Its lead product was AB0024, a humanized monoclonal antibody targeting the human lysyl oxidase-like-2 (LOXL2) protein, then in Phase I studies for idiopathic pulmonary fibrosis and advanced solid tumors. Founded circa 2007 and backed by Kleiner Perkins Caufield & Byers, HealthCare Ventures, Northgate Capital, DAG Ventures and Abbott Biotech Ventures, Arresto was acquired by Gilead Sciences for $225 million; the deal was announced December 20, 2010 and had closed by February 2011. The company no longer operates as an independent entity, publishes no developer or API surface, and its former domain (arrestobio.com) no longer resolves.

Arresto Biosciences is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Biopharmaceutical, and Life Sciences.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyHealthcareBiotechnologyBiopharmaceuticalLife SciencesDrug DiscoveryOncologyFibrosisMonoclonal AntibodiesAcquired

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/arresto-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Source (apis.yml)

aid: arresto-biosciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/arresto-biosciences.png
name: Arresto Biosciences
description: Arresto Biosciences, Inc. was a privately-held, development-stage biotechnology company headquartered in Palo
  Alto, California, focused on medicines to treat fibrotic diseases and cancer by targeting enzymes involved in the synthesis
  of the extracellular matrix. Its lead product was AB0024, a humanized monoclonal antibody targeting the human lysyl oxidase-like-2
  (LOXL2) protein, then in Phase I studies for idiopathic pulmonary fibrosis and advanced solid tumors. Founded circa 2007
  and backed by Kleiner Perkins Caufield & Byers, HealthCare Ventures, Northgate Capital, DAG Ventures and Abbott Biotech
  Ventures, Arresto was acquired by Gilead Sciences for $225 million; the deal was announced December 20, 2010 and had closed
  by February 2011. The company no longer operates as an independent entity, publishes no developer or API surface, and its
  former domain (arrestobio.com) no longer resolves.
url: https://raw.githubusercontent.com/api-evangelist/arresto-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- kleiner-perkins
x-status: acquired
x-status-detail: 'Acquired by Gilead Sciences (Nasdaq: GILD) for $225 million; announced 2010-12-20, closed Q1 2011. No longer
  an independent operating company.'
x-acquisition:
  acquirer: Gilead Sciences, Inc.
  acquirer_slug: gilead-sciences
  amount_usd: 225000000
  announced: '2010-12-20'
  closed_by: '2011-02-21'
  source: https://www.sec.gov/Archives/edgar/data/882095/000129993310004530/exhibit1.htm
x-former-website: http://www.arrestobio.com
x-investors:
- Kleiner Perkins Caufield & Byers
- HealthCare Ventures
- Northgate Capital
- DAG Ventures
- Abbott Biotech Ventures
x-headquarters: Palo Alto, California, United States
x-lead-asset: AB0024, humanized monoclonal antibody targeting LOXL2
x-api-surface: none
x-api-surface-reason: Defunct pre-clinical biotechnology company; never published a public API, developer portal, or documentation.
  Former domain does not resolve (no A/NS records, 2026-07-19).
x-tier: stub
x-tier-reason: defunct-acquired-no-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Healthcare
- Biotechnology
- Biopharmaceutical
- Life Sciences
- Drug Discovery
- Oncology
- Fibrosis
- Monoclonal Antibodies
- Acquired
apis: []
common:
- type: LLMsTxt
  url: llms/arresto-biosciences-llms.txt
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: minimal
  artifacts_added: 1
  pass: local-v1